Arrowhead Appoints Oye Olukotun to Board of Directors as the company advances its two important cardiometabolic candidates – Cardiology2.0

Posted: Published on September 13th, 2020

This post was added by Alex Diaz-Granados

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the board of directors appointed veteran pharmaceutical industry executive Oye Olukotun, M.D., MPH, as an independent director of the company, with a term beginning effective September 1, 2020.

Douglass Given, M.D., Ph.D., Chairman of the Board of Arrowhead, said, Oye is a senior physician executive, with deep scientific and clinical development experience across broad markets. His extensive and proven track record in successfully developing products through approval, particularly with cardiometabolic products, will be of tremendous value to Arrowhead as the company advances its two important cardiometabolic candidates, ARO-APOC3 and ARO-ANG3, into later stage development and continues to expand its broad pipeline.

Im thrilled to join the Board of Arrowhead Pharmaceuticals, said Dr. Olukotun. Arrowhead has an exciting pipeline of truly meaningful products and Im excited to help the company demonstrate their value.

Oye Olukotun is a Mayo Clinic trained Cardiologist who currently serves as the Chief Executive Officer of CR Strategies, LLC. He served as the CEO of Epigen Pharmaceuticals, Inc. from 2014 to 2017, and Vice Chairman of CardioVax, Inc., from 2012 to 2016. He spent the first 20 years of his career in roles of increasing responsibility in clinical development, including multiple product approvals, at Pfizer, Bristol-Myers Squibb, and Mallinckrodt. He has over 35 years of experience in the pharmaceutical industry and has been instrumental in the approval and success of numerous cardiology and metabolic medicines, including the first daily beta blocker and the first approved ACE inhibitor, among others. Dr. Olukotun currently serves on the board of directors for Tonix Pharmaceuticals Holding Corp. Dr. Olukotun received his Medical Doctor degree from the Albert Einstein College of Medicine in New York, and a Masters in Public Health from Harvard University School of Public Health.

Visit link:
Arrowhead Appoints Oye Olukotun to Board of Directors as the company advances its two important cardiometabolic candidates - Cardiology2.0

Related Posts
This entry was posted in Clinical Cardiology. Bookmark the permalink.

Comments are closed.